NASDAQ · GKOS
Healthcare · Medical - Devices
$171.68
Down-$6.22 (-3.62%)
Updated Sep 16, 2026, 6:16 PM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GKOS closed at $171.68 after 20 trading sessions, down 6.77% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $169.75 | $172.76 | $167.97 | $171.68 | 658.91K |
| Sep 14, 2026 | $168.51 | $171.36 | $165.43 | $171.09 | 906.31K |
| Sep 11, 2026 | $174.12 | $175.375 | $166.74 | $167.25 | 552.41K |
| Sep 10, 2026 | $176.50 | $179.96 | $169.26 | $170.38 | 1.01M |
| Sep 9, 2026 | $183.15 | $183.33 | $178.52 | $179.79 | 587.94K |
| Sep 8, 2026 | $175.55 | $185.35 | $172.98 | $185.04 | 1.16M |
| Sep 4, 2026 | $177.80 | $181.52 | $175.135 | $177.47 | 572.54K |
| Sep 3, 2026 | $180.80 | $181.295 | $178.72 | $180.35 | 610.19K |
| Sep 2, 2026 | $176.87 | $182.2798 | $176.35 | $179.53 | 768.72K |
| Sep 1, 2026 | $179.97 | $180.14 | $175.33 | $176.70 | 507.24K |
| Aug 31, 2026 | $178.67 | $180.075 | $174.28 | $179.56 | 455.57K |
| Aug 28, 2026 | $181.10 | $182.225 | $177.77 | $179.87 | 553.53K |
| Aug 27, 2026 | $178.51 | $183.315 | $178.43 | $181.91 | 442.31K |
| Aug 26, 2026 | $180.11 | $181.89 | $176.82 | $180.57 | 506.04K |
| Aug 25, 2026 | $186.21 | $187.14 | $179.20 | $181.39 | 639.69K |
| Aug 24, 2026 | $184.13 | $186.88 | $181.75 | $185.65 | 622.29K |
| Aug 21, 2026 | $185.00 | $187.60 | $183.68 | $184.89 | 440.1K |
| Aug 20, 2026 | $187.73 | $191.62 | $183.245 | $184.89 | 791.87K |
| Aug 19, 2026 | $186.00 | $190.06 | $185.96 | $189.55 | 505.43K |
| Aug 18, 2026 | $185.00 | $186.66 | $175.04 | $184.15 | 625.63K |
The latest Smart Investors Daily articles mentioning GKOS.
GKOS research
Company profile and research snapshot.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | BTIG | Buy | — |
| Jul 30, 2026 | Needham | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 30, 2026 | BTIG | Buy | — |
| Jul 30, 2026 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 10, 2026
Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.45%. Currently, Glaukos has a market capitalization of $10.58 billion.
Yahoo · Sep 1, 2026
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
ChartMill · Sep 1, 2026
GKOS fits a Minervini Trend Template + High Growth Momentum screen: strong uptrend, near 52-week high, top-tier relative strength, and accelerating revenue and EPS growth.
Yahoo · Aug 28, 2026
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GKOS.
